Literature DB >> 2893669

Intracoronary alpha 2-adrenergic receptor blockade attenuates ischemia in conscious dogs during exercise.

R Seitelberger1, B D Guth, G Heusch, J D Lee, K Katayama, J Ross.   

Abstract

Studies on the role of alpha-adrenergic constrictor tone in the coronary vascular bed during ischemia were performed in dogs running on a treadmill. The animals were instrumented with a left ventricular pressure transducer, and regional systolic wall thickening (%WTh) was assessed by sonomicrometry in the anterior and posterior walls of the left ventricle. An intracoronary catheter was implanted chronically in the circumflex coronary artery, and a hydraulic cuff was placed proximally around the artery. After beta-adrenergic blockade with propranolol (0.8 mg/kg i.v.), acute stenosis of the coronary artery was performed during running in five dogs to induce severe regional myocardial dysfunction in the posterior wall. Intracoronary infusion of the selective alpha 2-adrenergic blocking agent idazoxan (80 micrograms/kg) improved %WTh in the ischemic region from 5.1 +/- 1.6 to 10.8 +/- 2.8% (p less than 0.05), without any significant effect on the anterior wall. Blood flow to the subendocardium of the posterior wall (radioactive microspheres) increased from 0.17 +/- 0.05 to 0.45 +/- 0.30 (ml/min)/g (p less than 0.05). It is concluded that in exercising dogs subjected to beta-adrenergic blockade, significant postjunctional alpha 2-adrenergic receptor-mediated coronary vasoconstriction exists, even during severe ischemia. Regional alpha 2-adrenergic receptor blockade can reduce regional ischemia and improve contractile function by attenuating exercise-induced sympathetic vasoconstriction in this conscious animal model.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2893669     DOI: 10.1161/01.res.62.3.436

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  26 in total

Review 1.  Heart rate: a forgotten link in coronary artery disease?

Authors:  Kim M Fox; Roberto Ferrari
Journal:  Nat Rev Cardiol       Date:  2011-04-26       Impact factor: 32.419

Review 2.  Increased coronary tone in exertional angina: the beneficial effects of calcium antagonists.

Authors:  G Specchia; D Ardissino; S Ghio; P Barberis; M L Colombo; S De Servi
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

3.  Minimal alpha 1- and alpha 2-adrenoceptor-mediated coronary vasoconstriction in the anaesthetized swine.

Authors:  R Schulz; R J Oudiz; B D Guth; G Heusch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-10       Impact factor: 3.000

Review 4.  The renin-angiotensin system and coronary vasomotion.

Authors:  G Ertl; K Hu; W R Bauer; B Bauer
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

Review 5.  Pharmacology of acute effort angina.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 6.  No adrenergic constriction in isolated coronary arterioles?

Authors:  E O Feigl
Journal:  Basic Res Cardiol       Date:  1995 Jan-Feb       Impact factor: 17.165

Review 7.  Alpha 1-adrenergic tone does not influence the transmural distribution of myocardial blood flow during exercise in dogs with pressure overload left ventricular hypertrophy.

Authors:  D J Duncker; J Zhang; M J Crampton; R J Bache
Journal:  Basic Res Cardiol       Date:  1995 Jan-Feb       Impact factor: 17.165

Review 8.  Alpha-adrenergic control of coronary circulation in man.

Authors:  C Indolfi; A Rapacciuolo; M Condorelli; M Chiariello
Journal:  Basic Res Cardiol       Date:  1994 Sep-Oct       Impact factor: 17.165

Review 9.  Neuronal control of coronary blood flow.

Authors:  D Baumgart; G Heusch
Journal:  Basic Res Cardiol       Date:  1995 Mar-Apr       Impact factor: 17.165

10.  Alpha 1-adrenergic blockade reduces exercise-induced regional myocardial ischemia in dogs.

Authors:  B D Guth; T Miura; E Thaulow; G Heusch; J Ross
Journal:  Basic Res Cardiol       Date:  1993 May-Jun       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.